StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Equities research analysts at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the stock.

Bio-Path Price Performance

Shares of BPTH opened at $0.72 on Wednesday. The business’s 50-day moving average price is $0.89 and its 200 day moving average price is $1.32. Bio-Path has a 1-year low of $0.59 and a 1-year high of $12.00.

Hedge Funds Weigh In On Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.